Pomalidomide-PEG1-azide

$350$500

Products Details

Product Description

– Pomalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker.?Pomalidomide-PEG1-azide?can be used to design a?PROTAC BRD4 Degrader-1 (HY-133131)[1]. Pomalidomide-PEG1-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

Web ID

– HY-133138

Storage Temperature

– 4°C (Powder, protect from light)

Shipping

– Room Temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C17H16N6O6

References

– [1]Zhang F, et al. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide. Bioorg Med Chem. 2020 Jan 1;28(1):115228.

CAS Number

– 2133360-04-8

Molecular Weight

– 400.35

Compound Purity

– 95.19

SMILES

– O=C(NC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O)COCCN=[N+]=[N-]

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– DMSO : 62.5 mg/mL (ultrasonic;warming;heat to 60°C)

Target

– E3 Ligase Ligand-Linker Conjugates

Pathway

– PROTAC

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=